BOT 5.97% 35.5¢ botanix pharmaceuticals ltd

Ann: Ethics Approval for Phase 2 Atopic Dermatitis Study Received, page-179

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 3,544 Posts.
    lightbulb Created with Sketch. 318
    I am not too greedy in all this but I thought 27c,on acne alone would be nice considering phase 1 data was great. However MC is the determinant not share price so the game changed with the dermatitis cap raising. However we are at about 50m mx now.

    Four times this on two phase twos could not be considered greedy at all. It would be somewhat realistic considering these are billion dollar markets eagerly, and I mean eagerly awaiting new ground breaking treatments.

    Getting to phase 3 upon great phase 2s should be quite an easy thing to manage considering worldwide potential.

    We live in a conservative world at the moment so Valuations are not what they could be but sooner or later the massive potentials will be unlocked.

    Sitting in a pool in patong last June when we spiked and having my friend say sell some..... I didn't.

    We wait and dream to be honest. It is a tough road.
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
35.5¢
Change
0.020(5.97%)
Mkt cap ! $707.4M
Open High Low Value Volume
33.5¢ 36.0¢ 33.3¢ $2.622M 7.530M

Buyers (Bids)

No. Vol. Price($)
5 106888 35.0¢
 

Sellers (Offers)

Price($) Vol. No.
35.5¢ 462320 5
View Market Depth
Last trade - 16.10pm 26/11/2024 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.